Retinal Dystrophy
7
2
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
A Study of LX107 Gene Therapy in AIPL1-IRD Patients
Oral Metformin for Treatment of ABCA4 Retinopathy
Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy
Functional Assessments in Vision Impairment
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
High Resolution Optical Coherence Tomography